Biotech · Private company · Memphis, TN, US
Tavo Biotherapeutics
Track this companyFree. Adds Tavo Biotherapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Arm 1: TB0001 ophthalmic solution 0.9%Phase 2 · Primary Open - Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- Arm 2: TB0001 ophthalmic solution 1.2%Phase 2 · Primary Open - Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- TB0001 ophthalmic solution 1.5%Phase 2 · Primary Open - Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
- Timolol 0.05% eye dropsPhase 2 · Primary Open - Angle Glaucoma (POAG)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.PHASE2 · RECRUITING · started Oct 23, 2026ClinicalTrials.gov NCT07913074 · fetched Nov 12, 2026
NIH awards4
- Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering FormulationFiscal year 2025 · $1MNIH RePORTER 5R44EY036343-02 · fetched Nov 12, 2026
- Late-stage Pre-clinical Development and GMP Production of a First-in-Class Extended Release IOP-lowering FormulationFiscal year 2024 · $1.1MNIH RePORTER 1R44EY036343-01 · fetched Nov 12, 2026
- Development of a novel depot delivery system for a glaucoma therapeuticFiscal year 2024 · $56.9KNIH RePORTER 3R43EY035207-01S1 · fetched Nov 12, 2026
- Development of a novel depot delivery system for a glaucoma therapeuticFiscal year 2024 · $81.7KNIH RePORTER 3R43EY035207-01S2 · fetched Nov 12, 2026